2021 NeXT Level Biomarkers Symposium: Biomarker Discovery with ImmunoID NeXT Platform
2021 NeXT Level Biomarkers Symposium: Biomarker Discovery with Personalis NeXT Platform Erin Newburn, PhD Director, Field Applications Scientist
23 Jun, 2021
22 May, 2021
2021 AACR: Personalis Product Demo
2021 AACR Personalis Product Demo Advancing Biomarker Discovery: Enabling improved tumor immunogenomics through a comprehensive approach Travis Yates, PhD Field Applications Scientist This presentation will cover: Predicting patient response to immunotherapies requires a robust and comprehensive approach to tumor immunogenomics. By combining highly [...]
3 May, 2021
An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth.
An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth. Cancer Discovery March 2021 Hubert Lam et al. View Publication View PDF
3 May, 2021
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study.
CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. The Lancet Oncology January 2021 O'Hara, Mark H et al. View Publication
3 May, 2021
Whole-exome sequencing based immunogenomic profiling with potential clinical applicability in circulating cell-free DNA and tissue from advanced stage colorectal cancer patients.
Whole-exome sequencing based immunogenomic profiling with potential clinical applicability in circulating cell-free DNA and tissue from advanced stage colorectal cancer patients. Journal for ImmunoTherapy of Cancer November 2020 Feng Z, Scheuenpflug J, Tan M et al. View Publication View PDF
3 May, 2021
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer.
A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer. Cell October 2020 Ott, Patrick A et al. View Publication
3 May, 2021
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial.
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial. Nature Medicine September 7, 2020 Motzer, RJ, Robbins, PB, Powles, T et al. View Publication View PDF
3 May, 2021
Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma.
Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B-cell lymphoma. American Journal of Hematology January 2020 Herrera AF, Goy A, Mehta A et al. View Publication View PDF
3 May, 2021
Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.
Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. The Lancet Gastroenterology & Hepatology September 1, 2019 Lowery, Maeve A et al. View Publication
3 May, 2021
Ibrutinib for patients with rituximab-refractory Waldenström’s macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. The Lancet Oncology December 9, 2016 Dimopoulos, Meletios A et al. View Publication
